Health Care/Hospital

Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®

The company's proven ability to reduce symptoms of occasional depression with Affron®, and its strong focus on quality control, have helped it deliver a truly outstanding product LONDON, March 23, 2021 /PRNewswire/ -- Based on its recent analysis of the North American market for industrial enter...

2021-03-23 20:00 1614

Pharma Industry to Spend $4.5 Billion on Digital Transformation by 2030

While the creation, manufacture, and supply of COVID vaccines are grabbing attention, behind the scenes, pharma manufacturers are digitizing at pace LONDON, March 23, 2021 /PRNewswire/ -- Pharma 4.0 concepts are taking hold in pharmaceutical manufacturing. The industry's unique characteristics ar...

2021-03-23 16:00 1786

Diluent or Immuno-Reagent solutions for your diagnostic testing kits (Covid, Flu, etc.)

PARIS, March 23, 2021 /PRNewswire/ -- Unither Pharmaceuticals, the Blow-Fill-Seal (BFS) worldwide leader, provides diagnostic companies with capacity solutions and innovative technologies for their testing kits (Covid, Flu, etc.).

2021-03-23 15:04 2877

Taiko Pharmaceutical Officially Launches "Cleverin" in Mexico, Top Made-in-Japan Brand for Removing Viruses/Bacteria, Deodorization

OSAKA, Japan, March 23, 2021 /PRNewswire/ -- Together with a local distribution partner, Torishi S.A. de C.V., Taiko Pharmaceutical Co., Ltd. (hereinafter Taiko), based inOsaka, Japan, has announced the launch of "Cleverin," a top made-in-Japan brand (*1) among products for removing viruses/bacte...

2021-03-23 14:00 4377

Shockwave Announces Joint Venture In China with Genesis MedTech Group

SINGAPORE, March 23, 2021 /PRNewswire/ -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company has signed an agreement to form a joint venture with Genesis MedTe...

2021-03-23 11:38 9872

Northern Sydney Cancer Centre Partners with Sun Nuclear as Newest SunCHECK™ Platform Reference Site

MELBOURNE, Fla., March 23, 2021 /PRNewswire/ -- Sun Nuclear Corporation announced today thatAustralia's Northern Sydney Cancer Centre (NSCC) is now a reference site for theSunCHECK™ Quality Management Platform. The Centre joins leading clinics worldwide already in the reference site program. Glob...

2021-03-23 03:51 1923

CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Hungary

* Marks vaccine's first approval by an European Union member state, following Mexico, Pakistan and China * Continues to boost production capacity to meet increasing demand * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effectiv...

2021-03-23 00:43 4386

Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences' Anti-PD-1

BOSTON and BEIJING, March 22, 2021 /PRNewswire/ -- Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injecti...

2021-03-22 22:30 2123

PathogenDx Applauded by Frost & Sullivan for Its Ultra-rapid COVID-19 Testing Platform, DetectX-Rv Test

PathogenDx's disruptive nucleic acid-based test uses a multiplex microarray to rapidly identify, detect, and quantify multiple pathogens and viral strains SANTA CLARA, Calif., March 22, 2021 /PRNewswire/ -- Based on its recent analysis of the global molecular testing market,Frost & Sullivan recog...

2021-03-22 22:00 1991

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

SINGAPORE, March 22, 2021 /PRNewswire/ -- Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19's post-recovery complications, which include heart damage, diabetes and multi-system ...

2021-03-22 21:00 1794

Xylonix Reveals New Drug Compound for Combating Cancer and Abnormal Macrophages

SINGAPORE, March 22, 2021 /PRNewswire/ -- Xylonix, a Singapore-based biotech company, has developed a new immunity drug (010DS-Zn) that demonstrates potential for treating a variety of solid cancers and COVID-19's post-recovery complications, which include heart damage, diabetes and multi-system ...

2021-03-22 21:00 1996

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma

WOBURN, Mass., March 22, 2021 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90...

2021-03-22 20:30 1686

Insightful Science Joins Forces with Dotmatics to Form a Leading Cloud-First Scientific R&D Company

- Combined company will generate well over $100 million of ARR and signals a significant transformation in the future of software and data management in research labs. - Enabling over one million scientists to improve research and lab efficiency. - Facilitating rapid data access and exchange bet...

2021-03-22 19:03 3992

Tavotek Biotherapeutics Announces Completion of Round A1 and A2 Financing with over $20 Million Dollars

LOWER GWYNEDD, Pennsylvania, March 22, 2021 /PRNewswire/ -- Tavotek Biotherapeutics announces it has raised over $20M in Round A1 and Round A2 financing in the preceding two months. YuanBio Venture Capital led the A1 finance round followed by Oriza Holdings, Ming BioVentures, and New Alliance Ca...

2021-03-22 19:00 1559

RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland

TEL AVIV, Israel and RALEIGH, N.C., March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib[1] treatment on an...

2021-03-22 19:00 4253

Chime Biologics announces Marc Funk as new Board Director

WUHAN, China, March 22, 2021 /PRNewswire/ -- Chime Biologics is pleased to announce the appointment ofMarc Funk to its Board of Directors. Marc brings more than 20 years of leadership and industry experience in the global CDMO space. As the former CEO of Lonza Group, Marc has led the transformati...

2021-03-22 18:03 1742

Everest Medicines Announces Financial Results for Full Year Ended December 31, 2020

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-22 15:06 3498

Xinhua Silk Road: Nanjing Jiangbei New Area invites global partners to jointly promote dev. of life and health industry

BEIJING, March 22, 2021 /PRNewswire/ -- Nanjing Jiangbei New Area, a state-level new area in eastChina's Jiangsu Province, sent invitation to global investors to enterChina's buoyant life and health market, according to a promotion meeting held recently inShanghai. At present, the new pharmaceut...

2021-03-22 14:45 3715

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, March 22, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater ...

2021-03-22 10:40 4412

Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This study w...

2021-03-22 10:31 5163
1 ... 821822823824825826827 ... 857